BioSpace News Archive

Biotech Bay

BioPharm Executive: Money Talk

Venture capital is hopping, attracted to some of the past several years’ successes.

October 14, 2017
·
1 min read
·
Karl Thiel
Business

BioPharm Executive: Career Track

Kare Schultz will become Teva’s fourth CEO in a decade, and its second outsider.

October 14, 2017
·
1 min read
·
Karl Thiel
FDA

BioPharm Executive: The Rockville Files

Officially, there have been four new chemical entities have been approved since our last issue.

October 14, 2017
·
1 min read
·
Karl Thiel
Policy

BioPharm Executive: Legal Briefs

What’s the best way to address high drug prices? That’s a tough question, but one angle that gets less public attention is the high cost of early-stage development.

October 14, 2017
·
1 min read
·
Karl Thiel
Drug Development

BioPharm Executive: From the Bench to the Clinic

Alnylam’s victory with Patisiran in familial amyloid polyneuropathy (FAP) is significant for more than just the company and its patients.

October 14, 2017
·
1 min read
·
Karl Thiel
Business

BioPharm Executive: Golden Handshakes

Halozyme’s Enhanze drug delivery technology just won it a $105 million upfront payment from Bristol-Myers Squibb.

October 14, 2017
·
1 min read
·
Karl Thiel
around-the-web

October 14, 2017
·
1 min read
Business

Intercept Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH

TARGET PharmaSolutions is pleased to announce that Intercept (Nasdaq: ICPT) has extended its strategic partnership for TARGET-NASH to a multi-year agreement.

October 14, 2017
·
3 min read
Pharm Country

Olympus Announces Continued Expansion Of Its GI Endoscopic Device Line With ESD Innovations

Olympus among other core businesses, announced today the expansion of its EndoTherapy product line, building on the company’s commitment to innovation and advancement in the field of endoscopy and its history as a pioneer in Endoscopic Submucosal Dissection (ESD).

October 14, 2017
·
3 min read
BioCapital

CASI Pharma Announces $23.8M Registered Direct Offering Led By Existing Shareholders

CASI Pharma announced that it has entered into definitive agreements with certain institutional and accredited investors.

October 14, 2017
·
6 min read